Ainos' Losses Widen to $7.37M Amid Cash Burn, Reverse Stock Split

TL;DR

**Ainos is burning cash and resorting to reverse stock splits to stay listed, signaling deep financial trouble and making it a risky bet.**

AI Summary

Ainos, Inc. (AIMDW) reported a net loss of $7,371,012 for the six months ended June 30, 2025, an increase from a net loss of $6,509,832 for the same period in 2024. Revenues significantly increased to $110,870 for the six months ended June 30, 2025, compared to $20,729 in the prior year, though gross profit remained low at $91,700. Operating expenses rose to $7,000,258 from $6,137,702, driven by increased selling, general and administrative expenses of $3,364,374. The company's cash and cash equivalents decreased substantially from $3,892,919 at December 31, 2024, to $1,223,184 at June 30, 2025. Ainos completed a 1-for-5 reverse stock split on June 30, 2025, to maintain Nasdaq listing compliance, following a similar split in December 2023. The company also raised $719,358 in net proceeds from an At The Market (ATM) offering by selling 262,383 shares of common stock.

Why It Matters

Ainos' continued significant net losses and dwindling cash reserves, despite a revenue increase, signal a precarious financial position for investors. The repeated reverse stock splits (1-for-5 on June 30, 2025, and 1-for-5 on December 14, 2023) are a red flag, indicating persistent struggles to meet Nasdaq's minimum bid price requirements, which can erode investor confidence and make the stock less attractive. For employees and customers, the financial instability could raise concerns about the company's long-term viability and ability to fund its AI Nose and VELDONA therapeutic platforms. In the competitive AI and healthcare sectors, Ainos' cash burn and reliance on equity offerings for funding could hinder its ability to innovate and compete effectively against better-capitalized rivals.

Risk Assessment

Risk Level: high — Ainos reported a net loss of $7,371,012 for the six months ended June 30, 2025, and its cash and cash equivalents plummeted from $3,892,919 to $1,223,184 in the same period. The company has also executed two 1-for-5 reverse stock splits within a year (December 2023 and June 2025) to maintain Nasdaq compliance, indicating severe stock price underperformance and potential delisting risk.

Analyst Insight

Investors should exercise extreme caution and consider divesting, as Ainos' substantial cash burn, widening losses, and repeated reverse stock splits point to significant financial distress and a high risk of further share price depreciation. New investors should avoid AIMDW until a clear path to profitability and sustainable cash flow is demonstrated.

Financial Highlights

debt To Equity

N/A

revenue

$110,870

operating Margin

-6317.7%

total Assets

N/A

total Debt

N/A

net Income

-$7,371,012

eps

-$0.99

gross Margin

82.7%

cash Position

$1,223,184

revenue Growth

+434.5%

Key Numbers

• $7.37M — Net Loss (Increased from $6.51M in prior year for six months ended June 30, 2025)
• $1.22M — Cash and Cash Equivalents (Decreased from $3.89M at December 31, 2024)
• $110,870 — Revenues (Increased from $20,729 for six months ended June 30, 2025)
• $7.00M — Total Operating Expenses (Increased from $6.14M for six months ended June 30, 2025)
• $3.36M — Selling, General and Administrative Expenses (Increased from $2.07M for six months ended June 30, 2025)
• $719,358 — Net Proceeds from ATM Offering (Received from selling 262,383 shares of common stock)
• 1-for-5 — Reverse Stock Split Ratio (Effectuated on June 30, 2025, and December 14, 2023)
• $0.99 — Net Loss Per Common Share (Q2 2025) (Compared to $2.45 in Q2 2024)
• $2.02 — Net Loss Per Common Share (YTD 2025) (Compared to $5.30 in YTD 2024)
• 4,267,990 — Common Shares Outstanding (As of June 30, 2025, adjusted for reverse split)

Key Players & Entities

• Ainos, Inc. (company) — registrant
• Nasdaq Capital Market (regulator) — exchange where AIMD and AIMDW trade
• H.C. Wainwright & Co., LLC (company) — sales agent for At The Market Offering
• AI Nose (company) — proprietary scent digitization technology platform
• VELDONA (company) — low-dose oral interferon platform
• Ainos, Inc. (Cayman Islands) (company) — controlling shareholder
• Taiwan Carbon Nano Technology Corporation (company) — controlling shareholder
• Securities Act of 1933 (regulator) — governs ATM Offering
• SEC (regulator) — prospectus supplement filed with
• Board of Directors (person) — approved reverse stock splits

FAQ

Risk Factors

• Deteriorating Cash Position [high — financial]: Cash and cash equivalents decreased by $2,669,775, from $3,892,919 at December 31, 2024, to $1,223,184 at June 30, 2025. This significant burn rate, coupled with increasing operating expenses, raises concerns about the company's ability to fund operations without further capital raises.
• Persistent Net Losses [high — financial]: The company reported a net loss of $7,371,012 for the six months ended June 30, 2025, an increase from $6,509,832 in the prior year. This continued unprofitability strains financial resources and raises questions about long-term viability.
• Reverse Stock Split Necessity [medium — regulatory]: Ainos completed a 1-for-5 reverse stock split on June 30, 2025, following a similar split in December 2023. This action was necessary to regain compliance with Nasdaq's minimum bid price requirement, indicating ongoing struggles with market valuation and investor confidence.
• Rising Operating Expenses [medium — operational]: Total operating expenses increased to $7,000,258 for the six months ended June 30, 2025, up from $6,137,702 in the comparable period of 2024. The primary driver was a significant increase in Selling, General and Administrative (SG&A) expenses to $3,364,374, suggesting potential inefficiencies or increased investment in growth initiatives that are not yet yielding proportional revenue.
• Low Gross Profit Margin [medium — financial]: Despite a substantial increase in revenue to $110,870 for the six months ended June 30, 2025, from $20,729 in the prior year, the gross profit remained low at $91,700. This indicates a high cost of goods sold relative to revenue, impacting overall profitability.
• Dilution from ATM Offering [medium — financial]: The company raised $719,358 in net proceeds from an At The Market (ATM) offering by selling 262,383 shares. While providing necessary capital, such offerings can lead to significant dilution for existing shareholders, especially when executed frequently.

Industry Context

Ainos operates in the biotechnology or medical device sector, an industry characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Success often depends on innovation, clinical trial outcomes, and securing adequate funding for operations and expansion. The competitive landscape can be intense, with established players and numerous startups vying for market share and investment.

Regulatory Implications

The company's repeated need for reverse stock splits to maintain Nasdaq listing suggests ongoing scrutiny regarding its market performance and financial stability. Failure to meet listing requirements could result in delisting, severely impacting liquidity and investor confidence. Compliance with FDA or equivalent regulatory bodies for product approval remains a critical ongoing factor.

What Investors Should Do

1. Monitor cash burn rate closely: The significant decrease in cash reserves necessitates careful tracking of future cash flows and burn rate to assess runway and the need for further capital raises.
2. Analyze revenue drivers: Understand the sustainability and scalability of the revenue growth, particularly the cost of goods sold, to assess gross margin improvement potential.
3. Evaluate SG&A efficiency: Scrutinize the increased SG&A expenses to determine if they are strategically aligned with growth objectives and yielding adequate returns.
4. Assess long-term profitability path: Given the persistent net losses, investors should seek clarity on the company's strategy and timeline for achieving profitability.
5. Consider dilution impact: Evaluate the potential for future equity offerings and their dilutive effect on existing shareholdings.

Key Dates

• 2025-06-30: 1-for-5 Reverse Stock Split — Effectuated to regain compliance with Nasdaq's minimum bid price requirement, signaling potential past struggles with stock valuation.
• 2025-06-30: ATM Offering Completion — Raised $719,358 in net proceeds, providing liquidity but also potentially diluting existing shareholders.
• 2025-06-30: End of Period Reporting — Reflects a significant increase in revenue but also a widening net loss and a substantial decrease in cash reserves compared to year-end 2024.
• 2023-12-14: Previous Reverse Stock Split — Indicates a recurring need to adjust share structure to meet exchange listing requirements.

Glossary

At The Market (ATM) Offering

A type of public offering where a company sells its stock directly into the existing stock market over a period of time, typically through an at-the-market issuance facility agreement with an underwriter. (Ainos utilized this to raise capital, impacting share count and potentially diluting existing shareholders.)

Reverse Stock Split

A corporate action in which a company reduces the total number of its outstanding shares by consolidating them. This is often done to increase the per-share price. (Ainos has implemented this twice to maintain Nasdaq listing compliance, highlighting concerns about its stock price.)

Selling, General and Administrative Expenses (SG&A)

Costs incurred by a company that are not directly related to the production or procurement of goods or services. This includes marketing, advertising, salaries of administrative staff, and rent. (A significant increase in SG&A expenses drove the rise in total operating expenses, impacting the company's net loss.)

Net Loss Per Common Share

The portion of a company's profit or loss allocated to each outstanding share of common stock. Calculated by dividing net income (or loss) by the weighted-average number of outstanding common shares. (Ainos reported a net loss per share of $0.99 for Q2 2025, indicating ongoing unprofitability on a per-share basis.)

Year-Over-Year Comparison

For the six months ended June 30, 2025, Ainos reported a substantial revenue increase to $110,870 from $20,729 in the prior year, a growth of over 434%. However, this top-line improvement was overshadowed by a widening net loss of $7,371,012, up from $6,509,832. Operating expenses also climbed, driven by higher SG&A costs. The company's cash position deteriorated significantly, falling from $3,892,919 at the end of 2024 to $1,223,184 by mid-2025, underscoring a challenging financial trajectory despite revenue gains.

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share AIMD The Nasdaq Stock Mar

Filing Documents

• form10-q.htm (10-Q) — 1063KB
• ex31-1.htm (EX-31.1) — 12KB
• ex31-2.htm (EX-31.2) — 12KB
• ex32-1.htm (EX-32.1) — 8KB
• ex32-2.htm (EX-32.2) — 7KB
• 0001493152-25-011908.txt ( ) — 4708KB
• aimd-20250630.xsd (EX-101.SCH) — 32KB
• aimd-20250630_cal.xml (EX-101.CAL) — 46KB
• aimd-20250630_def.xml (EX-101.DEF) — 173KB
• aimd-20250630_lab.xml (EX-101.LAB) — 281KB
• aimd-20250630_pre.xml (EX-101.PRE) — 233KB
• form10-q_htm.xml (XML) — 611KB

Financial Statements

Financial Statements 3 Condensed Balance Sheets – June 30, 2025 (unaudited) and December 31, 2024 3 Condensed Statements of Operations – Three and six Months Ended June 30, 2025 and 2024 (unaudited) 4 Condensed Statements of Comprehensive Loss – Three and six Months Ended June 30, 2025 and 2024 (unaudited) 5 Condensed Statements of Stockholders' Equity– Three Months Ended June 30, 2025 and 2024 (unaudited) 6 Condensed Statements of Stockholders' Equity– Six Months Ended June 30, 2025 and 2024 (unaudited) 7 Condensed Statements of Cash Flows – Six Months Ended June 30, 2025 and 2024 (unaudited) 8 Notes to Condensed Financial Statements (unaudited) 9 ITEM 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 ITEM 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 26 ITEM 4.

Controls and Procedures

Controls and Procedures 27 PART II: OTHER INFORMATION 27 ITEM 1.

Legal Proceedings

Legal Proceedings 27 ITEM 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 28 ITEM 3. Defaults Upon Senior Securities 28 ITEM 4. Mine Safety Disclosures 28 ITEM 5. Other Information 28 ITEM 6. Exhibits 29

Signatures

Signatures 30 2 PART I - FINANCIAL INFORMATION ITEM 1. Financial Statements Ainos, Inc. Condensed Balance Sheets June 30, December 31, 2025 2024 (Unaudited) Assets Current assets: Cash and cash equivalents $ 1,223,184 $ 3,892,919 Accounts receivable 187 56 Inventory, net 160,057 143,756 Other current assets 350,549 301,077 Total current assets 1,733,977 4,337,808 Intangible assets, net 21,505,821 23,748,328 Property and equipment, net 495,109 559,645 Other assets 187,269 174,418 Total assets $ 23,922,176 $ 28,820,199 Liabilities and Stockholders' Equity Current liabilities: Contract liabilities $ - $ 106,329 Convertible notes payable (including amounts of related party of nil and $ 2,000,000 as of June 30, 2025, and December 31, 2024, respectively) - 3,000,000 Accrued expenses and others current liabilities 602,782 848,615 Total current liabilities 602,782 3,954,944 Convertible notes payable - noncurrent (including amounts of related party of $ 11,000,000 and $ 9,000,000 as of June 30, 2025 and December 31, 2024, respectively) 11,000,000 9,000,000 Other long-term liabilities 876,608 348,945 Total liabilities 12,479,390 13,303,889 Commitments and contingencies - - Stockholders' equity: Preferred stock, $ 0.01 par value; 50,000,000 shares authorized; none issued and outstanding as of June 30, 2025, and December 31, 2024, respectively - - Common stock, $ 0.01 par value; 300,000,000 shares authorized as of June 30, 2025, and December 31, 2024, 4,267,990 and 3,085,477 shares issued and outstanding as of June 30, 2025, and December 31, 2024, respectively (1) 42,680 30,854 Additional paid-in capital 71,668,502 68,644,301 Accumulated deficit ( 60,120,328 ) ( 52,749,316 ) Accumulated other comprehensive loss ( 148,068 ) ( 409,529 ) Total stockholders' equity 11,442,786 15,516,310 Total liabilities and stockholders' equity $ 23,922,176 $ 28,820,199

View Full Filing

View this 10-Q filing on SEC EDGAR